Risk of childhood cancer in infants treated with phototherapy for neonatal jaundice

Libor Vítek

DOI: https://doi.org/10.1038/s41390-024-03315-z

IF: 3.953

2024-06-10

Pediatric Research

Abstract:Phototherapy of neonatal jaundice was first introduced by Cremer et al. as early as 1958, 1 but further studies that focused on demonstrating its safety and efficacy by Lucey et al. were needed to become widely adopted. 2 Since then, phototherapy has become the gold standard in the treatment of neonatal jaundice in fact, approximately 8 million newborn infants are treated annually with phototherapy. 3 However, as early as 1975, Speck et al. had raised the first concern about the possible carcinogenic potential of phototherapy, when they demonstrated the mutagenicity of photoilluminated bilirubin on calf thymus DNA. 4 Illumination of DNA in the presence of bilirubin resulted in DNA alterations, while these changes were not observed when DNA was irradiated in the absence of bilirubin or when DNA mixed with bilirubin was kept in the dark (4), indicating that rather than phototherapy itself, the bilirubin photooxidation products were responsible for these effects. Importantly, these genotoxic effects were documented in a human study in lymphocytes from newborns treated with phototherapy. 5

pediatrics